Cardiff Oncology (NASDAQ:CRDF) Given New $13.00 Price Target at HC Wainwright

Cardiff Oncology (NASDAQ:CRDF) had its target price reduced by HC Wainwright from $14.00 to $13.00 in a report published on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Craig Hallum initiated coverage on shares of Cardiff Oncology in a research report on Friday, September 6th. They issued a “buy” rating and a $8.00 price objective for the company.

Cardiff Oncology Stock Performance

NASDAQ CRDF traded down $1.01 during trading on Friday, reaching $3.08. The company’s stock had a trading volume of 3,658,061 shares, compared to its average volume of 953,353. The firm has a market cap of $143.37 million, a price-to-earnings ratio of -3.38 and a beta of 1.93. Cardiff Oncology has a twelve month low of $0.94 and a twelve month high of $6.42. The business’s fifty day moving average price is $2.74 and its 200-day moving average price is $2.78.

Cardiff Oncology (NASDAQ:CRDF) last issued its earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.12 million. Cardiff Oncology had a negative net margin of 6,143.91% and a negative return on equity of 62.65%. During the same period in the previous year, the firm earned ($0.25) EPS. As a group, sell-side analysts forecast that Cardiff Oncology will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CRDF. Point72 DIFC Ltd bought a new stake in Cardiff Oncology in the 2nd quarter valued at about $27,000. Ground Swell Capital LLC bought a new stake in shares of Cardiff Oncology during the 2nd quarter worth about $38,000. Dimensional Fund Advisors LP raised its position in shares of Cardiff Oncology by 34.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock worth $42,000 after buying an additional 4,892 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Cardiff Oncology during the 3rd quarter worth about $64,000. Finally, Invst LLC bought a new stake in shares of Cardiff Oncology during the 2nd quarter worth about $74,000. 16.29% of the stock is currently owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.